QC
PRQR icon

Quadrature Capital’s ProQR Therapeutics PRQR Stock Holding History

Quadrature Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Buy
84,806
+72,771
+605% +$120K ﹤0.01% 1408
2026
Q1 		$19.5K Sell
12,035
-92,196
-88% -$151K ﹤0.01% 1312
2025
Q4 		$211K Buy
104,231
+68,091
+188% +$159K ﹤0.01% 958
2025
Q3 		$77.2K Buy
+36,140
New +$79K ﹤0.01% 912
2025
Q2 		– Sell
-26,403
Closed -$35.4K – 1393
2025
Q1 		$35.4K Buy
+26,403
New +$56.2K ﹤0.01% 1002

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Quadrature Capital's PRQR Position: Q2 2026 in Review

Quadrature Capital increased its ProQR Therapeutics (PRQR) stake by 605% in Q2 2026, buying an estimated $120K and bringing the position to 84,806 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #1408.

Quadrature Capital first reported a position in PRQR in Q1 2025 and has held it in 5 quarters since. The position peaked at $211K in Q4 2025. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Quadrature Capital held 84,806 shares of ProQR Therapeutics worth $158K as of Q2 2026.
  • Quadrature Capital bought 72,771 ProQR Therapeutics shares in Q2 2026, an estimated $120K.
  • ProQR Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1408 holding.
  • Quadrature Capital first reported a position in ProQR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Quadrature Capital's ProQR Therapeutics position peaked at $211K in Q4 2025.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.